A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

Trial Profile

A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2018

At a glance

  • Drugs Tagraxofusp (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Stemline Therapeutics
  • Most Recent Events

    • 24 Jan 2018 Planned number of patients changed from 35 to 29.
    • 15 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 15 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top